Synthetic Opioid key responses
- Mapping evidence-based key responses to synthetic opioids and their implementation strategies
- Field-tested Toolkit with seven implementation guides
M. Hellard et al. Achieving hepatitis C elimination in Europe – To treatment scale-up and beyond
The implication of this work is that for many countries the elimination of hepatitis C as a public health threat is not going to happen by chance. A number of barriers need to be overcome, requiring a focused effort from governments and health services. The first barrier is that widespread treatment scale-up is currently precluded by restricted and inconsistent access policies in many European countries.3,4
Micro-elimination – A path to global elimination of hepatitis C
The micro-elimination approach encourages policymakers and other stakeholders to set pragmatic national and subnational goals, while the people who are best informed about the nature of the HCV epidemic in their sub-population can take the lead in tailoring interventions to address its specific circumstances.
Legal Barriers for Providing HCV Community Testing in Europe
Correlation European Harm Reduction Network conducted a telephone survey with representatives of harm reduction services and of NGOs that offer low-threshold services to drug users. During the months of September and October 2018, a total of twenty (20) organizations in 18 countries, participated in this survey and provided information on the state of affairs with regards to community testing in their country
Hepatitis C virus reinfection after successful treatment with direct-acting antiviral therapy in a large population-based cohort
Direct-acting antiviral therapies (DAA) are an important tool for hepatitis C virus (HCV) elimination. However, reinfection among people who inject drugs (PWID) may hamper elimination targets. Therefore, we estimated HCV reinfection rates among DAA-treated individuals, including PWID.
Direct acting antiviral-based treatment of hepatitis C virus infection among people who inject drugs in Georgia: A prospective cohort study
People who inject drugs (PWID) are often excluded from HCV treatment programs due to concerns about their ability to adhere to care. Georgia has a high prevalence of HCV infection (5.4% of chronic cases in general population) with an epidemic concentrated among PWID. We evaluated adherence to care and sustained virologic response (SVR) among PWID in Georgia.
Scaling up prevention and treatment towards the elimination of hepatitis C: a global mathematical model. Alastair Heffernan et al.
We evaluated the impact of public health interventions on the global HCV epidemic and investigated whether WHO’s elimination targets could be met.
Achieving hepatitis C elimination in Europe – To treatment scale-up and beyond. M. Hellard et al.
The implication of this work is that for many countries the elimination of hepatitis C as a public health threat is not going to happen by chance. A number of barriers need to be overcome, requiring a focused effort from governments and health services. The first barrier is that widespread treatment scale-up is currently precluded by restricted and inconsistent access policies in many European countries.3,4
